Drugs / Ervebo
Ervebo
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Ervebo | — | 2019-11-11 | europa.eu ↗ |
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05202288 | Jan → Aug 2027 expected | Ebola hemorrhagic fever | ANRS, Emerging Infectious Diseases | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06100913 | Aug 2024 → Aug 2027 expected | Ebola hemorrhagic fever | Emory University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04822376 | Oct 2021 → Apr 2022 | Ebola hemorrhagic fever | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06841614 | Sep 2026 → Aug 2027 expected | Ebola hemorrhagic fever | ANRS, Emerging Infectious Diseases | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05959421 | Jun 2026 → Dec 2027 | Ebola hemorrhagic fever | University Medical Center Hamburg-Eppendorf | Withdrawn | No outcome recorded |
| Phase 3 | NCT06126822 | Feb 2025 → Oct 2026 expected | Ebola hemorrhagic fever | Institute of Tropical Medicine, Belgium | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06587503 | Oct → Dec 2024 overdue | COVID-19, Ebola hemorrhagic fever | University of Birmingham | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ervebo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04822376 ↗ |
| Known as | Recombinant Vesicular Stomatitis Vaccine for Ebola | “Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)” NCT06100913 ↗ |
| Known as | rVSV∆G-ZEBOV-GP | “Participants will receive ERVEBO® (rVSV∆G-ZEBOV-GP) ≥72 million pfu/mL primary immunization And a single booster immunization with the same dose of study vaccine as the primary...” NCT05959421 ↗ |
| Modality | Vaccine | “Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated)” NCT04822376 ↗ |
| Route | Intramuscular | “intramuscular vaccination” NCT05959421 ↗ |